- Direction
- Inflecting
- Own history
- 10th
- Peers
- 56th
- Persistence
- REVERSING
· Pharmaceutical Preparations
RESEARCH SNAPSHOTALNYLAM PHARMACEUTICALS, INC.'s latest supported as-filed period reports revenue of $1.5B. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.79% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 23.39% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 16.74% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 7.26% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 75.19% · CORE
Level · gp.fundamentals.operating_margin
Raw value 23.72% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 28.02% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 40.5%; Inventory / revenue moved 123 bp higher.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 16.7%; Operating margin moved 575 bp lower; Operating income decreased 6.0%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Gross margin moved 902 bp lower; Operating margin moved 575 bp lower.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 66.9%; Operating margin moved 2002 bp higher; Operating income changed across a sign change.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 475.1%; Capex / revenue moved 382 bp higher.
2 evidence-backed componentsCurrent liabilities changed +32.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ALNY · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001178670-26-000076SEC ↗8-KOct 29, 2026Period Oct 29, 20260001178670-26-000074SEC ↗4Oct 6, 2026Period Oct 2, 20260001178670-26-000068SEC ↗4Sep 22, 2026Period Sep 19, 20260001178670-26-000065SEC ↗10-QJul 30, 2026Period Jun 30, 20260001178670-26-000062SEC ↗8-KJul 30, 2026Period Jul 30, 20260001178670-26-000060SEC ↗4Jun 3, 2026Period Jun 1, 20260001178670-26-000048SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 2, 2026Filed Oct 6, 2026 | SUPRAN BRYANEVP, CLO and Secretary | Open Market SaleDirect | 1,758 | $227 | $398,855 | Form 4 ↗ |
| Sep 19, 2026Filed Sep 22, 2026 | Greenstreet YvonneChief Executive Officer | Grant Or AwardDirect | 107 | $0 | $0 | Form 4 ↗ |
| Jun 1, 2026Filed Jun 3, 2026 | PYOTT DAVID E IDirector | Option ExerciseDirect | 3,830 | $0 | $0 | Form 4 ↗ |
| Jun 1, 2026Filed Jun 3, 2026 | PYOTT DAVID E IDirector | Open Market SaleDirect | 921 | $298 | $274,191 | Form 4 ↗ |
| Jun 1, 2026Filed Jun 3, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 5.43% · OPTIONAL
Total assets changed +64.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed +29.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Inventory changed +40.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed -1127 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Operating margin changed -575 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating margin changed +2002 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001178670-26-000047| Open Market SaleDirect |
| 1,175 |
| $299 |
| $351,219 |
| Form 4 ↗ |
| Jun 1, 2026Filed Jun 3, 2026 | PYOTT DAVID E IDirector | Open Market SaleDirect | 1,222 | $300 | $366,441 | Form 4 ↗ |
| Jun 1, 2026Filed Jun 3, 2026 | PYOTT DAVID E IDirector | Open Market SaleDirect | 495 | $301 | $148,856 | Form 4 ↗ |
| Jun 1, 2026Filed Jun 3, 2026 | PYOTT DAVID E IDirector | Open Market SaleDirect | 17 | $303 | $5,145 | Form 4 ↗ |
| Jun 1, 2026Filed Jun 3, 2026 | PYOTT DAVID E IDirector | Option ExerciseDirect | 3,830 | $0 | $0 | Form 4 ↗ |
| Jun 1, 2026Filed Jun 3, 2026 | Cravatt BenjaminDirector | Grant Or AwardDirect | 4,393 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | Sigal Charles ElliottDirector | Grant Or AwardDirect | 671 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | Sigal Charles ElliottDirector | Grant Or AwardDirect | 1,441 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | SCHULMAN AMY WDirector | Grant Or AwardDirect | 838 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | SCHULMAN AMY WDirector | Grant Or AwardDirect | 1,802 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | Reitan Colleen FDirector | Grant Or AwardDirect | 671 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | Reitan Colleen FDirector | Grant Or AwardDirect | 1,441 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | PYOTT DAVID E IDirector | Grant Or AwardDirect | 671 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | PYOTT DAVID E IDirector | Grant Or AwardDirect | 1,441 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | KELLOGG PETER NDirector | Grant Or AwardDirect | 671 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | KELLOGG PETER NDirector | Grant Or AwardDirect | 1,441 | $0 | $0 | Form 4 ↗ |